Axcella Health Inc (NASDAQ:AXLA) Director David R. Epstein bought 5,796 shares of the stock in a transaction dated Wednesday, July 10th. The stock was bought at an average price of $8.24 per share, with a total value of $47,759.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of NASDAQ AXLA opened at $7.89 on Friday. Axcella Health Inc has a fifty-two week low of $7.70 and a fifty-two week high of $15.99. The company’s 50 day simple moving average is $11.44.

Axcella Health (NASDAQ:AXLA) last issued its quarterly earnings data on Thursday, June 20th. The company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($2.04). Equities research analysts forecast that Axcella Health Inc will post -3.05 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the company. Leerink Swann assumed coverage on Trevi Therapeutics in a research note on Monday, June 3rd. They issued an “outperform” rating for the company. JPMorgan Chase & Co. upgraded ROYAL MAIL PLC/ADR from an “underweight” rating to a “neutral” rating in a research note on Monday, June 3rd. Svb Leerink initiated coverage on Trevi Therapeutics in a research note on Monday, June 3rd. They set an “outperform” rating and a $14.00 price objective for the company. Finally, Goldman Sachs Group initiated coverage on Axcella Health in a research note on Sunday, June 2nd. They set a “buy” rating and a $25.00 price objective for the company.

About Axcella Health

There is no company description available for Axcella Health Inc

Recommended Story: How to identify percentage decliners

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.